GlaxoSmithKline and Google parent Alphabet's life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a novel field of medicine called bioelectronics. Verily Life Sciences – known as Google's life sciences unit until last year – and Britain's biggest drugmaker will together contribute 540 million pounds ($715 million) over seven years to Galvani Bioelectronics, they said on Monday. It is GSK's second notable investment in Britain since the country voted to leave the European Union in June.
Read the rest here:
GSK and Google parent forge $715 million bioelectronic medicines firm
